Currently, there are 96.27M common shares owned by the public and among those 90.35M shares have been available to trade.
The company’s stock has a 5-day price change of -11.86% and -16.45% over the past three months. AVDL shares are trading -6.87% year to date (YTD), with the 12-month market performance up to 23.36% higher. It has a 12-month low price of $10.25 and touched a high of $19.09 over the same period. AVDL has an average intraday trading volume of 934.53K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.83%, -3.82%, and -13.92% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares accounts for 71.91% of the company’s 96.27M shares outstanding.
It has a market capitalization of $1.27B and a beta (3y monthly) value of 1.42. The earnings-per-share (ttm) stands at -$1.15. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.95% over the week and 5.18% over the month.
Earnings per share for the fiscal year are expected to increase by 75.69%, and 219.28% over the next financial year. EPS should grow at an annualized rate of 15.00% over the next five years, compared to 4.78% over the past 5-year period.
Looking at the support for the AVDL, a number of firms have released research notes about the stock. Rodman & Renshaw stated their Buy rating for the stock in a research note on June 12, 2024, with the firm’s price target at $27. Oppenheimer coverage for the Avadel Pharmaceuticals plc (AVDL) stock in a research note released on March 05, 2024 offered a Outperform rating with a price target of $29. Needham was of a view on March 05, 2024 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on March 05, 2024, issuing a price target of $21- $25. UBS on their part issued Buy rating on February 06, 2024.
